*P<0.05, ** P<0.01 significant difference vs. healthy broliers. Ke:,elimination rate constant; Ka, absorption rate constant; t1/2a, the absorption half-life; t1/2e, the elimination half-life; Tmax, th

NIAID Data Ecosystem40

Protocol Deviation in Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants - Ondansetron

药代动力学

孕期用药安全

Protocol Deviation Information Study Description This master protocol included multiple drugs of interest (DOIs) being studied. The primary objective of this study was to evaluate the pharmacokinetics

NIAID Data Ecosystem30

Physical Examination Dataset in Multiple Dose Pharmacokinetic Study of Meropenem in Young Infants (<91 days) with Suspected or Complicated Intra-abdominal Infections

腹腔感染治疗

药代动力学

Timing and findings of physical exam, including system review and conditions or abnormalities Study Description An open-label, multiple-dose study to determine the safety, tolerability, and pharmacoki

NIAID Data Ecosystem50

Anonymized dataset of pyrazinamide pharmacokinetics.

抗结核药物

药代动力学

(CSV)

NIAID Data Ecosystem40

Pharmacokinetics of LtEc and PEG-LtEc.

资源简介：

相关数据集